New Strong Buy Stocks for October 22ndZacks Investment Research · 2 days ago
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPRNewsWire · 3 days ago
Immunic adds new Chief People Officer ahead of Phase 3 readoutProactive Investors · 5 days ago
Immunic Appoints Jaa Roberson as Chief People OfficerPRNewsWire · 5 days ago
Immunic, Inc. (NASDAQ:IMUX) Stock Has Consensus Target Price of $35.43 According to AnalystsDefense World · Oct 12, 2026
Immunic to present four vidofludimus calcium abstracts at MSToronto2026Proactive Investors · Oct 7, 2026Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$1.16 | -$0.80 | Beat |
| May 13, 2026 | -$0.71 | -$1.08 | Miss |
| Feb 26, 2026 | -$0.90 | -$1.20 | Miss |
| Nov 13, 2025 | -$0.18 | -$1.30 | Miss |
| Aug 7, 2025 | -$1.58 | -$2.00 | Miss |
| May 15, 2025 | -$2.50 | -$2.50 | Beat |